Recovery from psychosis : physical health, antipsychotic medication and the daily dilemmas for mental health nurses [PDF]
, 2015 This paper considers some of the dilemmas experienced by Mental Health Nurses everyday when faced with the seemingly conflicting relationships that exist between recovery, antipsychotics and the physical health of people experiencing psychosis.
Bressington, D. +3 more
core +1 more source
No association of a set of candidate genes on haloperidol side effects. [PDF]
, 2012 We previously investigated a sample of patients during an active phase of psychosis in the search for genetic predictors of haloperidol induced side effects.
De Ronchi, Diana +8 more
core +4 more sources
Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomised controlled treatment trials [PDF]
, 2006 Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive–compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory.
Carey, P +8 more
core +1 more source
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects [PDF]
BioMed Research International, 2014 Antipsychotic-induced extrapyramidal adverse effects are well recognized in the context of first-generation antipsychotic drugs. However, the introduction of second-generation antipsychotics, with atypical mechanism of action, especially lower dopamine receptors affinity, was met with great expectations among clinicians regarding their potentially ...
Nevena Divac +3 more
openaire +2 more sources
Nefazodone in psychotic unipolar and bipolar depression: A retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol [PDF]
, 2002 Although atypical antipsychotics are on the rise, traditional treatment of psychotic (or delusional) depression mostly includes the addition of classical antipsychotics to antidepressants. As there are only few data supporting this approach compared with
Born, Christoph +4 more
core +1 more source
Akathisia and second-generation antipsychotic drugs
Current Opinion in Psychiatry, 2009 Akathisa is one of the most common and distressing neuroleptic-induced extrapyramidal side effects. Although it is well recognized in the context of conventional antipsychotic medications, there have been recent concerns raised by clinicians and researchers that this syndrome is overlooked in relation to second-generation or atypical antipsychotics ...
Kumar, Rajeev, Sachdev, Perminder Singh
openaire +3 more sources
Indian Journal of Psychological Medicine, 2014 Background: Despite a large body of evidence, the issue of differences in adherence and continuation of treatment with first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) in schizophrenia remains unresolved.
Nisha Warikoo +2 more
doaj +1 more source
Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case
European Psychiatry, 2023 Introduction Schizophrenia affects people worldwide. In Europe, the advantages of second-generation and long-acting injectable antipsychotics (SG-LAIs) are known and used, supported by scientific evidence.
J. Galvañ, F. R. Nguepy-Keubo
doaj +1 more source
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients [PDF]
, 2008 We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic
Bilušić, Hrvoje +5 more
core +1 more source
Are Second Generation Antipsychotics a Distinct Class? [PDF]
Journal of Psychiatric Practice, 2008 Second generation antipsychotic medications have become synonymous with "atypicality." To support the clinical lore of equivalent efficacy with reduced risk of extrapyramidal symptoms, clinical trials have overwhelmingly chosen a high-potency first-generation antipsychotic (e.g., haloperidol) as a comparator.
Caroline, Bonham, Christopher, Abbott
openaire +2 more sources